1329834-05-0
Chemical Structure
2-Hydroxy nevirapine-d3
- CAS No.: 1329834-05-0
- Formula:C15H11D3N4O2
- Molecular Weight:285.32
IUPAC Name: 11-cyclopropyl-2-hydroxy-4-(methyl-d3)-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
InChIKey: LFZSOJABLBVGRJ-FIBGUPNXSA-N
SMILES: [2H]C([2H])(C1=CC(O)=NC2=C1NC(C3=CC=CN=C3N2C4CC4)=O)[2H]
Biological Activity: 2-Hydroxy nevirapine-d3 (2-OH NVP-d3) is the deuterated-labeled 2-Hydroxy nevirapine (2-OH NVP) (HY-W739986). 2-Hydroxy nevirapine (2-OH NVP) is a phase I metabolite of Nevirapine (HY-10570) and an Aryl Hydrocarbon Receptor activator. It induces hepatic Apolipoprotein A1 levels and modulates paraoxonase-1 enzyme activity. 2-Hydroxy nevirapine is used in research on atherosclerosis and HIV-1 infection[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2-Hydroxy nevirapine-d3 | 2-Hydroxy nevirapine-d3 (2-OH NVP-d3) is the deuterated-labeled 2-Hydroxy nevirapine (2-OH NVP) (HY-W739986). 2-Hydroxy nevirapine (2-OH NVP) is a phase I metabolite of Nevirapine (HY-10570) and an Aryl Hydrocarbon Receptor activator. It induces hepatic Apolipoprotein A1 levels and modulates paraoxonase-1 enzyme activity. 2-Hydroxy nevirapine is used in research on atherosclerosis and HIV-1 infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Hydroxy nevirapine | 2-Hydroxy nevirapine (2-OH NVP) is a phase I metabolite of Nevirapine (HY-10570) and an Aryl Hydrocarbon Receptor activator. It induces hepatic Apolipoprotein A1 levels and modulates paraoxonase-1 enzyme activity. 2-Hydroxy nevirapine is used in research on atherosclerosis and HIV-1 infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Marinho AT, et al. The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies. Pharmacological research. 2021 Mar;165:105446. [Content Brief]
- [2]. Aline T, et al. Development and validation of an HPLC-UV method for quantifying nevirapine and its main phase I metabolites in human blood. Anal. Methods 2014; 6 (5): 1575-1580.
- [3]. Pinheiro PF, et al. Sex differences in hepatic and intestinal contributions to nevirapine biotransformation in rats. Chemico-biological interactions. 2015 May 25;233:115-21.
- [4]. Marinho AT, et al. Nevirapine modulation of paraoxonase-1 in the liver: An in vitro three-model approach. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2016 Jan 20;82:147-53.
